Down-regulation of integrin α2 surface expression by mutant epidermal growth factor receptor (EGFRvIII) induces aberrant cell spreading and focal adhesion formation

Cancer Research

Volumn 65, Issue 20, 2005, Pages 9280-9286

  Ning, Yan ^a   Zeineldin, Reema ^b   Liu, Yueying ^c   Rosenberg, Martina ^a   Stack, M Sharon ^c   Hudson, Laurie G ^a  

^a UNIVERSITY OF NEW MEXICO   (United States)

^b University of New Mexico   (United States)

^c NORTHWESTERN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 (3 CHLOROANILINO) 6,7 DIMETHOXYQUINAZOLINE; ACTIN; ALPHA2 INTEGRIN; EPIDERMAL GROWTH FACTOR; EPIDERMAL GROWTH FACTOR RECEPTOR; MUTANT PROTEIN; TYRPHOSTIN;

ARTICLE; AUTOPHOSPHORYLATION; CANCER CELL CULTURE; CATALYSIS; CELL SHAPE; CELL SPREADING; CONTROLLED STUDY; DIMERIZATION; FLOW CYTOMETRY; FOCAL ADHESION; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; OVARY CANCER; PHENOTYPE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; RECEPTOR BINDING; RECEPTOR INTRINSIC ACTIVITY; SIGNAL TRANSDUCTION; WESTERN BLOTTING;

AMINO ACID SEQUENCE; CATALYSIS; CELL LINE, TUMOR; COLLAGEN TYPE I; DOWN-REGULATION; FEMALE; FOCAL ADHESIONS; HUMANS; INTEGRIN ALPHA2; MOLECULAR SEQUENCE DATA; MUTATION; OVARIAN NEOPLASMS; RECEPTOR, EPIDERMAL GROWTH FACTOR;

EID: 27144453307     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-05-0407     Document Type: Article

References (50)

1. Jemal A, Murray T, Samuels A, Ghafoor A, Ward E, Thun MJ. Cancer statistics, 2003. CA Cancer J Clin 2003;53:5-26.
2. Jemal A, Tiwari RC, Murray T, et al. Cancer statistics, 2004. CA Cancer J Clin 2004;54:8-29.
3. Auersperg N, Wong AS, Choi KC, Kang SK, Leung PC. Ovarian surface epithelium: biology, endocrinology, and pathology. Endocr Rev 2001;22:255-88.
4. Ozols RF, Bookman MA, Connolly DC, et al. Focus on epithelial ovarian cancer. Cancer Cell 2004;5:19-24.
5. Skubitz AP. Adhesion molecules. Cancer Treat Res 2002;107:305-29.
6. Hood JD, Cheresh DA. Role of integrins in cell invasion and migration. Nat Rev Cancer 2002;2:91-100.
7. Felding-Habermann B. Integrin adhesion receptors in tumor metastasis. Clin Exp Metastasis 2003;20:203-13.
8. 1 integrin. Int J Cancer 1996;67:695-701.
9. 1-integrin-mediated interaction with type I collagen. Invasion Metastasis 1998;18:15-26.
10. 1 integrin. Cancer Res 1999;59:1635-41.
11. Brunelleschi S, Penengo L, Santoro MM, Gaudino G. Receptor tyrosine kinases as target for anti-cancer therapy. Curr Pharm Des 2002;8:1959-72.
12. Janmaat ML, Giaccone G. Small-molecule epidermal growth factor receptor tyrosine kinase inhibitors. Oncologist 2003;8:576-86.
13. Lynch TJ, Bell DW, Sordella R, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 2004;350:2129-39.
14. Pedersen MW, Tkach V, Pedersen N, Berezin V, Poulsen HS. Expression of a naturally occurring constitutively active variant of the epidermal growth factor receptor in mouse fibroblasts increases motility. Int J Cancer 2004;108:643-53.
15. Price DK, Figg WD. Mutations in the EGFR: the importance of genotyping. Cancer Biol Ther 2004;3: 434-5.
16. Kuan CT, Wikstrand CJ, Bigner DD. EGF mutant receptor vIII as a molecular target in cancer therapy. Endocr Relat Cancer 2001;8:83-96.
17. Allen LF, Lenehan PF, Eiseman IA, Elliott WL, Fry DW. Potential benefits of the irreversible pan-erbB inhibitor, CI-1033, in the treatment of breast cancer. Semin Oncol 2002;29:11-21.
18. Lorimer IA. Mutant epidermal growth factor receptors as targets for cancer therapy. Curr Cancer Drug Targets 2002;2:91-102.
19. Moscatello DK, Holgado-Madruga M, Godwin AK, et al. Frequent expression of a mutant epidermal growth factor receptor in multiple human tumors. Cancer Res 1995;55:5536-9.
20. Montgomery RB, Klein-Szanto A, Ross E, Godwin A. Expression of a mutant EGFR in ovarian cancer. Proc Am Assoc Cancer Res 2004;45:1800.
21. Moscatello DK, Montgomery RB, Sundareshan P, McDanel H, Wong MY, Wong AJ. Transformational and altered signal transduction by a naturally occurring mutant EGF receptor. Oncogene 1996;13:85-96.
22. Antonyak MA, Moscatello DK, Wong AJ. Constitutive activation of c-Jun N-terminal kinase by a mutant epidermal growth factor receptor. J Biol Chem 1998;273:2817-22.
23. 1-dependent EGF receptor activation at cell-cell contact sites. J Cell Sci 2000;113:2139-47.
24. Reginato MJ, Mills KR, Paulus JK, et al. Integrins and EGFR coordinately regulate the pro-apoptotic protein Bim to prevent anoikis. Nat Cell Biol 2003;5:733-40.
25. Cabodi S, Moro L, Bergatto E, et al. Integrin regulation of epidermal growth factor (EGF) receptor and of EGF-dependent responses. Biochem Soc Trans 2004;32:438-42.
26. Di Stefano P, Cabodi S, Boeri Erba E, et al. P130Cas-associated protein (p140Cap) as a new tyrosine-phosphorylated protein involved in cell spreading. Mol Biol Cell 2004;15:787-800.
27. 2- integrin sub-unit expression on human carcinoma cells upon EGF-receptor activation. Int J Cancer 1999;80: 546-52.
28. Li J, Lin ML, Wiepz GJ, Guadarrama AG, Bertics PJ. Integrin-mediated migration of murine B82L fibroblasts is dependent on the expression of an intact epidermal growth factor receptor. J Biol Chem 1999;274:11209-19.
29. Mariotti A, Kedeshian PA, Dans M, Curatola AM, Gagnoux-Palacios L, Giancotti FG. EGF-R signaling through Fyn kinase disrupts the function of integrin α6β4 at hemidesmosomes: role in epithelial cell migration and carcinoma invasion. J Cell Biol 2001;155: 447-58.
30. Klekotka PA, Santoro SA, Wang H, Zutter MM. Specific residues within the α2 integrin subunit cytoplasmic domain regulate migration and cell cycle progression via distinct MAPK pathways. J Biol Chem 2001;276:32353-61.
31. 2 integrin subunit cytoplasmic domain-dependent cellular migration requires p38 MAPK. J Biol Chem 2001;276:9503-11.
32. 2 integrin subunit. Exp Cell Res 1993;209:216-23.
33. 1 integrin cell-surface expression protects A431 cells from epidermal growth factor-induced apoptosis. Int J Cancer 2000;87:360-7.
34. Masuho Y, Zalutsky M, Knapp RC, Bast RC, Jr. Interaction of monoclonal antibodies with cell surface antigens of human ovarian carcinomas. Cancer Res 1984;44:2813-9.
35. Ellerbroek SM, Hudson LG, Stack MS. Proteinase requirements of epidermal growth factor-induced ovarian cancer cell invasion. Int J Cancer 1998;78:331-7.
36. Ellerbroek SM, Halbleib JM, Benavidez M, et al. Phosphatidylinositol 3-kinase activity in epidermal growth factor-stimulated matrix metalloproteinase-9 production and cell surface association. Cancer Res 2001;61:1855-61.
37. Berchuck A, Olt GJ, Everitt L, Soisson AP, Bast RC, Boyer CM. The role of peptide growth factors in epithelial ovarian cancer. Obstet Gynecol 1990;75:255-62.
38. Rodriguez GC, Berchuck A, Whitaker RS, Schlossman D, Clarke-Pearson DL, Bast RC, Jr. Epidermal growth factor receptor expression in normal ovarian epithelium and ovarian cancer. II. Relationship between receptor expression and response to epidermal growth factor. Am J Obstet Gynecol 1991;164:745-50.
39. Humphrey PA, Wong AJ, Vogelstein B, et al. Anti-synthetic peptide antibody reacting at the fusion junction of deletion-mutant epidermal growth factor receptors in human glioblastoma. Proc Natl Acad Sci USA 1990;87:4207-11.
40. Ellerbroek SM, Wu Y, Overall CM, Stack MS. Functional interplay between type I collagen and cell surface matrix metalloproteinase activity. J Biol Chem 2001;276:24833-42.
41. 1 integral expression. Exp Cell Res 1995;216:261-72.
42. Nagane M, Narita Y, Mishima K, et al. Human glioblastoma xenografts overexpressing a tumor-specific mutant epidermal growth factor receptor sensitized to cisplatin by the AG1478 tyrosine kinase inhibitor. J Neurosurg 2001;95:472-9.
43. Burleson KM, Casey RC, Skubitz KM, Pambuccian SE, Oegema TR, Jr., Skubitz AP. Ovarian carcinoma ascites spheroids adhere to extracellular matrix components and mesothelial cell monolayers. Gynecol Oncol 2004;93:170-81.
44. Genersch E, Schneider DW, Sauer G, Khazaie K, Schuppan D, Lichtner RB. Prevention of EGF-modulated adhesion of tumor cells to matrix proteins by specific EGF receptor inhibition. Int J Cancer 1998;75:205-9.
45. 1 integrin abrogates the malignant phenotype of breast carcinoma cells. Proc Natl Acad Sci USA 1995;92:7411-5.
46. 1 modulates EGF stimulation of Rho GTPase-dependent morphological changes in adherent human rhabdomyosarcoma RD cells. J Cell Physiol 2005;202:754-66.
47. Katsumi A, Orr AW, Tzima E, Schwartz MA. Integrins in mechanotransduction. J Biol Chem 2004;279:12001-4.
48. Bershadsky AD, Balaban NQ, Geiger B. Adhesion-dependent cell mechanosensitivity. Annu Rev Cell Dev Biol 2003;19:677-95.
49. Ingber DE. Tensegrity II. How structural networks influence cellular information processing networks. J Cell Sci 2003;116:1397-408.
50. Chen CS, Alonso JL, Ostuni E, Whitesides GM, Ingber DE. Cell shape provides global control of focal adhesion assembly. Biochem Biophys Res Commun 2003;307:355-61.